“A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN-1).” The presentation will describe the ...
33 rd Annual Meeting of the Diabetic Neuropathy Study Group (NeuroDiab), Sept. 28-Oct. 1; Thessaloniki, Greece; Oral Presentation 59 th Annual Meeting of the European Association for the Study of ...
Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin Date: September 4, 2025 Time: 4:00 ...
THE WOODLANDS, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), announced today that data from a poster highlighting XERMELO ® (telotristat ethyl) will be ...
THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its ...
Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback